Events
Gene Therapy for Hemophilia Studied.
The Medical College of Wisconsin received a five-year, $1.8 million grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to investigate therapies for hemophilia A. Qizhen Shi, MD, PhD, assistant professor of pediatric hematology/oncology at the Medical College, and a researcher at Children’s Hospital of Wisconsin and the BloodCenter of Wisconsin, is the principal investigator for the grant.
Alliance for Cancer Gene Therapy Welcomes Applications for Young Investigator Awards.
The Alliance for Cancer Gene Therapy, the only public charity in the United States dedicated exclusively to funding cancer gene therapy research, is accepting abstract submissions for its Fund for Discovery Young Investigators awards.
A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma.
The aim of this phase I clinical trial was to assess the feasibility and safety of intratumoral administration of a first-generation adenoviral vector encoding herpes simplex virus thymidine kinase (HSV-TK) gene (Ad.TK) followed by systemic ganciclovir to patients with advanced hepatocellular carcinoma (HCC).
A 17-year-old Cambridge biotechnology firm is betting $35 million in new financing on the success of its budding gene therapy program.
This spring, Genetix Pharmaceuticals reinvented itself as the developer of treatments for two rare and devastating genetic disorders.
Left untreated, both diseases — the blood disorder beta-thalassemia major and the brain-wasting disease Adrenoleukodystrophy, or ALD — are fatal. And existing treatments can be as dangerous as the diseases.
Left untreated, both diseases — the blood disorder beta-thalassemia major and the brain-wasting disease Adrenoleukodystrophy, or ALD — are fatal. And existing treatments can be as dangerous as the diseases.
Georgetown U. Hospital closes lab after problems with breast cancer tests.
Georgetown University Hospital has shut down a lab that performs genetic analysis for breast cancer patients and has had 249 women's tissue samples independently retested while federal health officials investigate procedures at the lab.
Integral Molecular Announces Key Patent Issued on Lipoparticle Technology for Deriving High Concentrations of Cell-free Membrane Proteins.
PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. today announced the issuance of a key patent covering its technology for deriving high concentrations of membrane proteins.